SpondyloarthritisPhase 3SELECT-AXIS 2NCT04169373
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
A Phase 3 study testing Upadacitinib in people with Spondyloarthritis, run by AbbVie at 212 sites in 25 countries.
Trial summary
This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently. The main objectives of this protocol are: To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adults with active axial spondyloarthritis… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Spondyloarthritis
- What is being tested?
- Upadacitinib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 734 participants
- Where
- 212 sitesin 25 countries
- Study dates
- 26 Nov 2019to 28 Feb 2025
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Study 1:
- Must have a clinical diagnosis of ankylosing spondylitis (AS) and meet the modified New York Criteria for AS,
- Must not have total spinal ankylosis
- Must have been previously exposed to 1 or 2 bDMARDs (at least 1 tumor necrosis factor [TNF] inhibitor or 1 interleukin [IL]-17 inhibitor [IL-17i]), and must have discontinued the bDMARD therapy due to either lack of efficacy (after at least 12 weeks of treatment with a bDMARD at an adequate dose) or intolerance (irrespective of treatment duration). Prior exposure to two bDMARDs was allowed for no more than 30% of patients; among patients with prior exposure to two bDMARDs, a lack of efficacy to one bDMARD and intolerance to another was permitted, but a patient could not have a lack of efficacy to two bDMARDs
- Study 2:
- Must have a clinical diagnosis of nr-axSpA fulfilling the 2009 Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA but not meeting the radiologic criterion of the modified New York criteria for AS
Show all 11Show fewer
- Must have objective signs of active inflammation consistent with axSpA on magnetic resonance imaging (MRI) of sacroiliac (SI) joints or based on high sensitivity C-reactive protein (hsCRP) > the upper limit of normal (ULN).
- Prior treatment with at most one bDMARD (either TNF inhibitor or IL-17i) is allowed for at least 20% but no more than 35% of enrolled patients who had to discontinue the prior bDMARD due to either lack of efficacy (after ≥ 12 weeks at an adequate dose) or intolerance (regardless of treatment duration).
- Must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4 at the Screening and Baseline Visits.
- Must have a Total Back Pain score ≥ 4 based on a 0 - 10 numerical rating scale at the Screening and Baseline Visits.
- Has had an inadequate response to at least 2 nonsteroidal anti-inflammatory drugs (NSAIDs) over an at least 4-week period in total at maximum recommended or tolerated doses, or has an intolerance to or contraindication for NSAIDs as defined by the Investigator.
Who cannot join
- Must not have been exposed to any Janus kinase (JAK) inhibitor (including but not limited to upadacitinib [Rinvoq®], tofacitinib [Xeljanz®], baricitinib [Olumiant®], filgotinib, ruxolitinib [Jakafi®], abrocitinib [PF-04965842], and peficitinib [Smyraf®]).
- Prior bDMARD therapy must be washed out.
- Participant must not have a history of an allergic reaction or significant sensitivity to constituents of the study drug.
Trial locations and contacts
212 sites in 25 countries.
212 sites in 25 countries
United States41 sites
Tekton Research, Inc. /ID# 214923
Austin, Texas, 78745
Arthritis & Rheumatic Disease Specialties /ID# 215306
Aventura, Florida, 33180
Rheumatology and Pulmonary Clinic /ID# 214946
Beckley, West Virginia, 25801
Tufts Medical Center /ID# 215925
Boston, Massachusetts, 02111-1552
Trinity Universal Research Associates - Carrollton /ID# 214948
Carrollton, Texas, 75007
Great Lakes Clinical Trials /ID# 215790
Chicago, Illinois, 60640
Arthritis and Osteoporosis Clinic Of Brazos Valley /ID# 215805
College Station, Texas, 77845
Denver Arthritis Clinic /ID# 215346
Denver, Colorado, 80230
Wayne State University Health Center /ID# 215930
Detroit, Michigan, 48201-2153
Altoona Ctr Clinical Res /ID# 214770
Duncansville, Pennsylvania, 16635
St. Paul Rheumatology /ID# 215537
Eagan, Minnesota, 55121
Arizona Arthritis & Rheumatology Associates, P.C. /ID# 215282
Flagstaff, Arizona, 86001-6269
Tekton Research /ID# 215054
Fort Collins, Colorado, 80528
JPS Rheumatology Clinic /ID# 215962
Fort Worth, Texas, 76104-4917
Klein and Associates MD /ID# 214767
Hagerstown, Maryland, 21740
Sweet Hope Research Specialty Inc /ID# 215931
Hialeah, Florida, 33016-1897
Memorial Rheumatology /ID# 216311
Houston, Texas, 77024-2420
Biopharma Informatic, LLC /ID# 215885
Houston, Texas, 77043
Biopharma Informatic - Park Row /ID# 215907
Houston, Texas, 77084
Newport Huntington Medical Group /ID# 216281
Huntington Beach, California, 92648-5994
Advanced Rheumatology, PC /ID# 214973
Lansing, Michigan, 48910
Cape Fear Arthritis Care /ID# 215927
Leland, North Carolina, 28451
West Texas Clinical Research /ID# 215928
Lubbock, Texas, 79410-1198
Marietta Memorial Hospital /ID# 215929
Marietta, Ohio, 45750-1635
NYU Langone Orthopedic Center /ID# 215594
New York, New York, 10016-2772
Health Research of Oklahoma /ID# 215117
Oklahoma City, Oklahoma, 73103-2400
Innovation Medical Research Center /ID# 216068
Palmetto Bay, Florida, 33157-1737
AZ Arthritis and Rheumotology Research, PLLC /ID# 215113
Phoenix, Arizona, 85032-9306
Trinity Universal Research Associates, Inc /ID# 215189
Plano, Texas, 75024-5283
Oregon Health and Science University /ID# 216446
Portland, Oregon, 97239
St. Lawrence Health System /ID# 215844
Potsdam, New York, 13676
Greater Chicago Specialty Physicians /ID# 216213
Schaumburg, Illinois, 60195-3106
Clinic of Robert Hozman/Clinical Investigation Specialists /ID# 215055
Skokie, Illinois, 60076
West Virginia Research Inst /ID# 214921
South Charleston, West Virginia, 25309
STAT Research, Inc. /ID# 215264
Springboro, Ohio, 45066
Clinvest Research LLC /ID# 215785
Springfield, Missouri, 65807
CenterPointe Institute of Research /ID# 215793
St Louis, Missouri, 63128-3841
Arizona Arthritis & Rheumatology Research, PLLC /ID# 214731
Tucson, Arizona, 85704
Inland Rheum & Osteo Med Grp /ID# 215807
Upland, California, 91786
Conquest Research /ID# 215804
Winter Park, Florida, 32789
Clinical Pharmacology Study Group /ID# 215293
Worcester, Massachusetts, 01605
Russia19 sites
Chelyabinsk Regional Clinical Hospital /ID# 214463
Chelyabinsk, Chelyabinsk Oblast, 454087
Alliance Biomedical Ural Group /ID# 214457
Izhevsk, Udmurtiya Republic, 426061
Immanuel Kant Baltic Federal University /ID# 218259
Kaliningrad, Kaliningrad Oblast, 236016
Kazan State Medical University /ID# 214421
Kazan', Tatarstan, Respublika, 420012
LLC Family Outpatient Clinic № /ID# 214455
Korolev, Moscow, 141060
Research Institute of Rheumatology named after V.A. Nasonova /ID# 214459
Moscow, Moscow, 115522
Olla-Med Clinic /ID# 214460
Moscow, 105554
City Clinical Hospital n.a. O.M. Filatov /ID# 214486
Moscow, 111539
LLC Medical Center /ID# 214410
Novosibirsk, Novosibirsk Oblast, 630099
Omsk Regional Clinic Hospital /ID# 214464
Omsk, 644111
Orenburg State Medical University /ID# 214408
Orenburg, 460000
LLC Novaya Klinika /ID# 214420
Pyatigorsk, Stavropol Kray, 357500
Ryazan State Medical University named after academician I.P. Pavlov /ID# 214418
Ryazan, 390026
Nort-Western State Medical University n.a. Mechnikov /ID# 214454
Saint Petersburg, Sankt-Peterburg, 193015
Clinical Rheumatologic Hospital No 25 /ID# 214488
Saint Petersburg, 190068
RZD-Medicine Saratov /ID# 214465
Saratov, 410004
Ulyanovsk Regional Clinical Hospital /ID# 214458
Ulyanovsk, 432017
Family Clinic /ID# 214737
Yekaterinburg, Sverdlovsk Oblast, 620109
Central City Hospital #7 /ID# 214741
Yekaterinburg, Sverdlovsk Oblast, 620137
Japan16 sites
National Hospital Organization Asahikawa Medical Center /ID# 214930
Asahikawa-shi, Hokkaido, 070-8644
Juntendo University Hospital /ID# 214929
Bunkyo-ku, Tokyo, 113-8431
St.Luke's International Hospital /ID# 215414
Chuo-ku, Tokyo, 104-8560
National Hospital Organization Osaka Minami Medical Center /ID# 214205
Kawachinagano Shi, Osaka, 586-8521
Kobe University Hospital /ID# 214598
Kobe, Hyōgo, 650-0017
Kuwana City Medical Center /ID# 215196
Kuwana-shi, Mie-ken, 511-0061
Matsuyama Red Cross Hospital /ID# 216021
Matsuyama, Ehime, 790-8524
Nagasaki University Hospital /ID# 215947
Nagasaki, Nagasaki, 852-8501
Daido Clinic /ID# 214735
Nagoya, Aichi-ken, 457-8511
Hyogo College of Medicine College Hospital /Id# 215638
Nishinomiya-shi, Hyōgo, 663-8501
Japanese Red Cross Okayama Hospital /ID# 214732
Okayama, Okayama-ken, 700-8607
Kita-harima Medical Center /ID# 216069
Ono-shi, Hyōgo, 675-1327
Osaka City General Hospital /ID# 215640
Osaka, Osaka, 534-0021
Hokkaido University Hospital /ID# 215221
Sapporo, Hokkaido, 060-8648
Sasebo Chuo Hospital /ID# 214703
Sasebo-shi, Nagasaki, 857-1195
Okinawa Prefectural Chubu Hospital /ID# 215575
Uruma, Okinawa, 904-2293
Ukraine16 sites
MNPE Chernihiv Regional Hospital of the Chernihiv Region Council /ID# 214145
Chernihiv, 14029
State Institution L.T. Malaya Therapy National Institute of the NAMS of Ukraine /ID# 214155
Kharkiv, 61039
CNCE of Kharkiv Regional Council Regional Clinical Hospital /ID# 214158
Kharkiv, 61058
MNI City Multidisciplinary Hospital #18 /ID# 214154
Kharkiv, 61110
Khmelnytskyi Regional Hospital /ID# 214153
Khmelnytskyi, 29000
MI Kryvyi Rih City Clinical Hospital No.2 /ID# 214152
Kryvyi Rih, 50056
Medical Center LLC Institute of Rheumatology /ID# 214146
Kyiv, 02081
Kyiv Railway Clinical Hosp No.2 /ID# 214779
Kyiv, 03049
Medical Center CONSILIUM MEDICAL /ID# 216234
Kyiv, 04050
MNI KRC Kyiv Regional Clinical Hospital /ID# 214156
Kyiv, 04107
Municipal Non-Commercial Enterprise Odesa Regional Clinical Hospital of the Od /ID# 214159
Odesa, 65025
Multifield Medical Centre of ONMU /ID# 214149
Odesa, 65026
PI "Poltava Regional Clinical Hospital n.a. M.V.Sklifosovsky" /ID# 214151
Poltava, 36011
Ternopil University Hospital /ID# 214705
Ternopil, 46002
CNE Vinnytsya Regional Clinical Hospital named after N.I.Pirogov /ID# 214147
Vinnytsia, 21028
Clinic of Scientific Research Institute of Invalid Rehabilitation /ID# 214148
Vinnytsia, 21029
China11 sites
The First Affiliated Hospital of BaoTou Medical College, Inner Mongolia Universi /ID# 216612
Baotou, Inner Mongolia, 014016
Peking Union Medical College Hospital /ID# 216545
Beijing, Beijing Municipality, 100730
The first affiliated hospital of bengbu medical college /ID# 216609
Bengbu, Anhui, 233004
Guangdong Provincial People's Hospital /ID# 216645
Guangzhou, Guangdong, 510080
Anhui Provincial Hospital /ID# 216631
Hefei, Anhui, 230001
First Affiliated Hospital of Kunming Medical University /ID# 217945
Kunming, 650032
Huashan Hospital, Fudan University /ID# 216646
Shanghai, Shanghai Municipality, 200040
The First Affiliated Hospital of Shantou University Medical College /ID# 217883
Shantou, Guangdong, 515041
Shenzhen People's Hospital /ID# 225438
Shenzhen, Guangdong, 518020
The First Affiliated Hospital of Soochow University /ID# 216607
Suzhou, Jiangsu, 215006
Zhuzhou Central Hospital /ID# 216644
Zhuzhou, Hunan, 412007
Czechia11 sites
REVMACLINIC s.r.o. /ID# 215153
Brno, 602 00
Revmacentrum MUDr. Mostera, s.r.o. /ID# 215161
Brno, 615 00
Revmatologie, s.r.o. /ID# 215309
Brno, 638 00
CCR Ostrava, s.r.o. /ID# 215226
Ostrava, 702 00
ARTHROHELP, s.r.o. /ID# 215224
Pardubice, 530 02
Revmatologicky ustav v Praze /ID# 215154
Prague, 128 00
PV MEDICAL Services s.r.o. /ID# 215119
Prague, 130 00
Revmatologicka ambulance - MUDr. Zuzana Urbanova /ID# 215652
Prague, 140 00
Thomayerova nemocnice /ID# 215118
Prague, 140 59
Fakultni Nemocnice v Motole /ID# 215160
Prague, 150 06
MEDICAL PLUS, s.r.o. /ID# 215324
Uherské Hradiště, 686 01
Germany9 sites
Rheumatologische Schwerpunktpraxis Brandt-Juergens /ID# 214282
Berlin, 12161
Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 214211
Berlin, 12203
Rheuma Research Lausitz, Dr. Mario Sutowicz /ID# 214218
Cottbus, 30342
Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 214207
Dresden, 01307
Universitaetsklinikum Erlangen /ID# 214281
Erlangen, Bavaria, 91054
Praxisgemeinschaft Rheumatologie Nephrologie Erlangen /ID# 214212
Erlangen, 91056
MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH /ID# 214208
Hamburg, 20095
Medizinische Hochschule Hannover /ID# 214209
Hanover, 30625
MVZ für Rheumatologie Dr. M. Welcker GmbH /ID# 214261
Planegg, 82152
Bulgaria8 sites
UMHAT Kaspela EOOD /ID# 214803
Plovdiv, 4001
Medical center Unimed /ID# 214816
Plovdiv, 4023
MHAT Plovdiv /ID# 214815
Plovdiv, 4027
Medical center Teodora /ID# 214813
Rousse, 7012
Medical center Excelsior /ID# 214805
Sofia, 1407
UMHAT Sveti Ivan Rilski /ID# 214804
Sofia, 1431
UMHAT Sveti Ivan Rilski /ID# 214806
Sofia, 1431
Diagnostic consultative center 17 Sofia /ID# 214808
Sofia, 1505
Hungary8 sites
Betegapolo Irgalmasrend Budai Irgalmasrendi Korhaz /ID# 215183
Budapest, 1023
Debreceni Egyetem Klinikai Kozpont /ID# 215187
Debrecen, Hajdú-Bihar, 4032
Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz /ID# 215186
Gyula, 5700
Hevizgyogyfurdo es Szent Andras Reumakorhaz /ID# 215184
Hévíz, 8380
Pest Megyei Flor Ferenc Korhaz /ID# 214501
Kistarcsa, 2143
Rehavita Kft HU /ID# 215188
Kormend, Zala County, 9900
CMED Rehabilitacios es Diagnosztikai Kozpont /ID# 215181
Székesfehérvár, 8000
Vital Medical Center Orvosi es Fogaszati Kozpont /ID# 215182
Veszprém, Veszprém megye, 8200
Argentina7 sites
Organizacion Medica de Investigacion (OMI) /ID# 214557
Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires, 1015
Hospital Cordoba /ID# 215846
Córdoba, 5000
Instituto Medico Strusberg /ID# 215239
Córdoba, 5000
Centro de Enfermedades del Hígado y Aparato Digestivo /ID# 214556
Rosario, Santa Fe Province, 2000
Instituto CAICI /ID# 215242
Rosario, Santa Fe Province, 2000
Centro de Investigaciones Medicas Tucuman /ID# 214559
San Miguel de Tucumán, Tucumán Province, 4000
Cimer /Id# 215240
San Miguel de Tucumán, 4000
South Korea7 sites
Gachon University Gil Medical Center /ID# 214534
Incheon, 21565
Hanyang University Seoul Hospital /ID# 214297
Seoul, Seoul Teugbyeolsi, 04763
Seoul National University Hospital /ID# 214532
Seoul, 03080
Kyunghee University Hospital at Gangdong /ID# 214296
Seoul, 05278
Asan Medical Center /ID# 214294
Seoul, 05505
The Catholic University of Korea, Seoul St. Mary's Hospital /ID# 214295
Seoul, 06591
Ajou University Hospital /ID# 214533
Suwon, Gyeonggido, 16499
Spain7 sites
Hospital Universitario Reina Sofia /ID# 214968
Córdoba, 14004
Hospital Universitario La Paz /ID# 216032
Madrid, 28046
Consorci Corporacio Sanitaria Parc Tauli Sabadell /ID# 214967
Sabadell, Barcelona, 08208
Hospital Unversitario Marques de Valdecilla /ID# 214965
Santander, Cantabria, 39008
Hospital Universitario y Politecnico La Fe /ID# 214966
Valencia, 46026
Hospital Meixoeiro (CHUVI) /ID# 214969
Vigo, Pontevedra, 36213
Hospital Marina Baixa /ID# 215970
Villajoyosa, Alicante, 03570
Poland6 sites
Osteo-Medic S.C. /ID# 214351
Bialystok, Podlaskie Voivodeship, 15-351
REUMED Sp.z o.o. Filia nr 1 /ID# 214353
Lublin, Lublin Voivodeship, 20-607
ETYKA-Osrodek Badan Klinicznych /ID# 215572
Olsztyn, Warmian-Masurian Voivodeship, 10-117
AI Centrum Medyczne Sp. z o.o. sp.k. /ID# 214354
Poznan, Greater Poland Voivodeship, 61-113
Nasz Lekarz Przychodnie Medyczne /ID# 214352
Torun, Kuyavian-Pomeranian Voivodeship, 87-100
WroMedica I. Bielicka, A. Strzalkowska s.c. /ID# 215093
Wroclaw, Lower Silesian Voivodeship, 51-685
Australia5 sites
Emeritus Research Sydney /ID# 215507
Botany, New South Wales, 2019
Emeritus Research /ID# 215506
Camberwell, Victoria, 3124
Monash Medical Centre /ID# 215509
Clayton, Victoria, 3168
Barwon Rheumatology Services /ID# 215508
Geelong, Victoria, 3220
BJC Health /ID# 215510
Parramatta, New South Wales, 2150
Brazil5 sites
EDUMED Educacao em Saude S/S L /ID# 215111
Curitiba, Paraná, 80440-080
CMiP - Centro Mineiro de Pesquisa Ltda - ME /ID# 215277
Juiz de Fora, Minas Gerais, 36010-570
LMK Sevicos Medicos S/S /ID# 215112
Porto Alegre, Rio Grande do Sul, 90480-000
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 215176
São José do Rio Preto, São Paulo, 15090-000
CPCLIN - Centro de Pesquisas Clínicas /ID# 215175
São Paulo, 01228-200
Canada5 sites
Applied Medical Informatics Research Inc. (AMIR) /ID# 215303
Montreal, Quebec, H4A 3T2
Centre de recherche du CHUQ /ID# 215038
Québec, G1R 3S2
Toronto Western Hospital /ID# 215041
Toronto, Ontario, M5T 2S8
Centre de Recherche Musculo-Squelettique /ID# 215096
Trois-Rivières, Quebec, G8Z 1Y2
Percuro Clinical Research, Ltd /ID# 215302
Victoria, British Columbia, V8V 3M9
Slovakia5 sites
Univerzitna nemocnica Bratislava Nemocnica Stare Mesto /ID# 214675
Bratislava, 813 69
Reum.hapi s.r.o. /ID# 224268
Nové Mesto nad Váhom, 915 01
Narodny ustav reumatickych chorob /ID# 214674
Piešťany, 921 12
MUDr. Zuzana Cizmarikova s.r.o. /ID# 215220
Poprad, 058 01
ALBAMED s.r.o. /ID# 215248
Zvolen, 960 01
Taiwan5 sites
Kaohsiung Veterans General Hos /ID# 214332
Kaohsiung City, Taichung, 81362
Far Eastern Memorial Hospital /ID# 215384
New Taipei City, 22060
Chung Shan Medical University Hospital /ID# 214018
Taichung, 40201
China Medical University Hospital /ID# 214019
Taichung, 40447
Cathay General Hospital /ID# 214183
Taipei, 10630
France4 sites
CHU Bordeaux - Hopital Pellegrin /ID# 214784
Bordeaux, 33000
Hopital Ambroise Pare /ID# 214783
Boulogne-Billancourt, 92104
AP-HP - Hopital Cochin /ID# 214782
Paris, 75014
CHU Toulouse /ID# 214780
Toulouse, Occitanie, 31300
Israel4 sites
Bnai Zion Medical Center /ID# 215856
Haifa, 3339419
Meir Medical Center /ID# 217255
Kfar Saba, 4428164
The Chaim Sheba Medical Center /ID# 215854
Ramat Gan, Tel Aviv, 5265601
Tel Aviv Sourasky Medical Center /ID# 216956
Tel Aviv, Tel Aviv, 6423906
United Kingdom4 sites
Doncaster Royal Infirmary /ID# 214971
Armthorpe Road, DN2 5LT
West Suffolk Hospital /ID# 215529
Bury St Edmunds, Suffolk, IP33 2QZ
Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 214865
Norwich, Norfolk, NR4 7UY
Minerva Health Centre /ID# 216226
Preston, Lancashire, PR1 6SB
Belgium3 sites
ReumaClinic /ID# 215005
Genk, 3600
UZ Gent /ID# 215004
Ghent, Oost-Vlaanderen, 9000
Universitair Ziekenhuis Leuven /ID# 215006
Leuven, Vlaams-Brabant, 3000
Turkey (Türkiye)3 sites
Istanbul University Cerrahpasa Faculty of Medicine /ID# 214895
Cerrahpaşa, 34098
Mugla Sitki Kocman University Medical Faculty /ID# 215358
Muğla, 48000
Hacettepe Universitesi Tip Fak /ID# 214898
Sihhiye, Ankara, 06100
New Zealand2 sites
Waikato Hospital /ID# 215503
Hamilton, Waikato Region, 3240
Middlemore Clinical Trials /ID# 215502
Papatoetoe, Auckland, 2025
Mexico1 site
CINTRE, Centro de Investigación y Tratamiento Reumatológico SC /ID# 215217
Mexico City, Mexico City, 11850
About this study
Official title: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects With Axial Spondyloarthritis Followed by a Remission-Withdrawal Period
This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently.
The main objectives of this protocol are:
- To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adults with active axial spondyloarthritis (axSpA) including biologic disease-modifying antirheumatic drug inadequate responders (bDMARD-IR) ankylosing spondylitis (AS) (Study 1) and non-radiographic axial spondyloarthritis (nr-axSpA) (Study 2).
- To assess the safety and tolerability of upadacitinib in adults with active axSpA including bDMARD-IR AS (Study 1) and nr-axSpA (Study 2).
- To evaluate the safety and tolerability of upadacitinib in extended treatment in adult participants with active axSpA including bDMARD-IR AS who have completed the Double-Blind Period (Study 1) and nr-axSpA who have completed the Double-Blind Period (Study 2).
- To evaluate the maintenance of disease control after withdrawal of upadacitinib.
Read the detailed description
Study 1 (bDMARD-IR AS) is comprised of a 14-week randomized, double-blind, parallel-group, placebo-controlled period (the Double-Blind Period); a 90-week open-label, long-term extension period (the Open-Label Extension Period); and a 30-day Follow-Up Visit (F/U Visit).
Study 2 (nr-axSpA) is comprised of a 52-week randomized, double-blind, parallel-group, placebo-controlled period (the Double-Blind Period); a 52-week open-label, long-term extension period (the Open-Label Extension Period); and a 30-day F/U Visit.
In the Double-Blind Period for both studies, participants are randomized in a 1:1 ratio to receive either upadacitinib or placebo once daily (QD).
Participants in the placebo group switch to upadacitinib 15 mg QD at Week 14 in the Open-Label Extension Period for Study 1 (bDMARD-IR AS) and Week 52 in the Open-Label Extension Period for Study 2 (nr-axSpA).
Participants in remission at Week 104 have the option to enroll in a remission-withdrawal period.
Study M19-944 protocol uses a common screening platform for determining eligibility into Study 1 and Study 2. Each study has its own objectives, hypothesis testing, randomization, data collection, and adequate power for primary and secondary endpoints. Analysis and reporting are conducted separately and independently for each study.
- Conditions
- Spondyloarthritis
- Being tested
- Upadacitinib, Placebo
- Keywords
- Upadacitinib, Axial Spondyloarthritis (axSpA), Spondyloarthritis, Ankylosing Spondylitis (AS)
- Medical subject headings
- Spondylarthritis, Axial Spondyloarthritis, Spondylitis, Ankylosing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
UpadacitinibDrug
Also called ABT-494, RINVOQ
Upadacitinib tablet administered orally
PlaceboDrug
Placebo for upadacitinib tablet administered orally
| Study group | Role | What they receive |
|---|---|---|
| Study 1: Upadacitinib 15 mg | Experimental | Participants receive 15 mg upadacitinib orally once a day for 104 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment). Receives: Drug: Upadacitinib |
| Study 1: Placebo | Placebo comparator | Participants receive matching placebo for 14 weeks and then switch to receive 15 mg upadacitinib orally once a day for 90 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment). Receives: Drug: Upadacitinib; Drug: Placebo |
| Study 2: Upadacitinib 15 mg | Experimental | Participants receive 15 mg upadacitinib orally once a day for 104 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment). Receives: Drug: Upadacitinib |
| Study 2: Placebo | Placebo comparator | Participants receive matching placebo for 52 weeks and then switch to receive 15 mg upadacitinib orally once a day for 52 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment). Receives: Drug: Upadacitinib; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Study 1: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society 40 (ASAS40) Response at Week 14
ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of > 0 units) in the potential remaining domain:
- Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity);
- Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
- Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
- Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Measured: Baseline and Week 14
Study 2: Percentage of Participants Achieving an ASAS40 Response at Week 14
ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of > 0 units) in the potential remaining domain:
- Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity);
- Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
- Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
- Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Measured: Baseline and Week 14
Secondary outcomes (35)
Study 1: Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 14
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:
- Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
- Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
- Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
- Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
- High-sensitivity C-reactive protein (hs-CRP) in mg/L.
The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS < 1.3) and very high disease (ASDAS > 3.5). A negative change from Baseline score indicates improvement in disease activity.
Measured: Baseline and Week 14
Study 1: Change From Baseline in Magnetic Resonance Imaging (MRI) Spondyloarthritis Research Consortium of Canada (SPARCC) Score for the Spine at Week 14
In the SPARCC MRI assessment of the spine, the entire spine was evaluated for active inflammation (bone marrow edema). Six discovertebral units (DVU) representing the 6 most abnormal DVUs were selected to calculate the MRI Spine SPARCC score. For each of the 6 DVUs, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all three dimensions.
Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least one quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice.
The maximum (worst) overall score for all 6 DVUs is 108. A negative change from Baseline indicates improvement.
Measured: Baseline and Week 14
Study 1: Percentage of Participants With Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response at Week 14
The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale [NRS]) pertaining to symptoms experienced for the past week. For Questions 1 to 5 (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity.
A BASDAI 50 response is defined as improvement of 50% or more from Baseline in BASDAI score.
Measured: Baseline and Week 14
Study 1: Percentage of Participants With an ASAS20 Response at Week 14
ASAS20 response was defined as an improvement of ≥ 20% and an absolute improvement of ≥ 1 unit (on a scale of 0 to 10) from Baseline in at least 3 of the following 4 domains, with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 units [on a scale of 0 to 10]) in the remaining domain:
- Patient's global assessment of disease activity, measured on a NRS from 0 (no activity) to 10 (severe activity);
- Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
- Function, measured by the BASFI which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
- Inflammation, measured by the mean of the 2 morning stiffness-related BASDAI NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Measured: Baseline and Week 14
Study 1: Percentage of Participants With ASDAS Inactive Disease at Week 14
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:
- Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
- Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
- Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
- Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
- High-sensitivity C-reactive protein (hs-CRP) in mg/L.
The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score < 1.3.
Measured: Week 14
Study 1: Change From Baseline in Patient's Assessment of Total Back Pain at Week 14
Participants assessed their total back pain during the last week on a 0 to 10 numerical rating scale (NRS), where 0 represents no pain and 10 represents most severe pain.
Measured: Baseline and Week 14
Study 1: Change From Baseline in Patient's Assessment of Nocturnal Back Pain at Week 14
Participants assessed the amount of back pain at night over the last week on a 0 to 10 NRS, where 0 represents no pain and 10 represents most severe pain.
Measured: Baseline and Week 14
Study 1: Percentage of Participants With ASDAS Low Disease Activity at Week 14
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:
- Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
- Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
- Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
- Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
- High-sensitivity C-reactive protein (hs-CRP) in mg/L.
The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score < 2.1.
Measured: Week 14
Study 1: Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14
The Bath Ankylosing Spondylitis Functional Index is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities such as putting on socks, bending, reaching, getting up from the floor or an armless chair, standing, climbing and other physical activities. Each item is scored on a NRS ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher scores indicating more functional limitations. A negative change from Baseline in BASFI indicates improvement.
Measured: Baseline and Week 14
Study 1: Percentage of Participants With ASAS Partial Remission at Week 14
ASAS partial remission (PR) is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains:
- Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity);
- Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
- Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
- Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Measured: Week 14
Study 1: Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score at Week 14
The ASQoL consists of 18 items related to quality of life, including the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. Each item is answered as yes (scored as 1) or no (scored as 0).
Scores are summed to obtain the overall score which ranges from 0 to 18, where higher scores indicate a worse quality of life. A negative change from Baseline in ASQoL indicates improvement in quality of life.
Measured: Baseline and Week 14
Study 1: Change From Baseline in ASAS Health Index at Week 14
The ASAS health index (HI) measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. Each of the 17 questions is answered by the participant as "I agree" (score = 1) or "I disagree" (score = 0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, where a higher score indicates a worse health status. A negative change from Baseline indicates improvement.
Measured: Baseline and Week 14
Study 1: Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMI[Lin]) at Week 14
The BASMI is a composite score based on 5 direct measurements of spinal mobility:
- cervical rotation (measured in degrees),
- tragus to wall distance (in centimeters [cm])
- lumbar side flexion (in cm),
- lumbar flexion (modified Schober's) (in cm) and
- intermalleolar distance (in cm).
Each measurement is converted to a linear score between 0 and 10. The total BASMI(lin) score is the average of the 5 scores and ranges from 0 to 10; the higher the BASMI(lin) score the more severe the patient's limitation of movement due to their ankylosing spondylitis. A negative change from Baseline indicates improvement.
Measured: Baseline and Week 14
Study 1: Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 14
The MASES evaluation was conducted to assess the presence or absence of enthesitis (inflammation of the entheses, or sites where tendons or ligaments insert into the bone) at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right. Each site was scored for presence (1) or absence (0) of enthesitis. The MASES is the sum of the 13 site scores, and ranges from 0 to 13, with higher scores indicating more inflammation of the entheses. A negative change from Baseline indicates improvement.
Measured: Baseline and Week 14
Study 1: Change From Baseline in MRI SPARCC Score for Sacroiliac Joints at Week 14
In the SPARCC MRI assessment of the sacroiliac (SI) joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema.
Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant.
The total maximum (worst) score for all SI joints across 6 slices is 72. A negative change from Baseline indicates improvement.
Measured: Baseline and Week 14
Study 2: Change From Baseline in ASDAS at Week 14
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:
- Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
- Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
- Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
- Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
- High-sensitivity C-reactive protein (hs-CRP) in mg/L.
The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS < 1.3) and very high disease (ASDAS > 3.5). A negative change from Baseline score indicates improvement in disease activity.
Measured: Baseline and Week 14
Study 2: Change From Baseline in MRI SPARCC Score for SI Joints at Week 14
In the SPARCC MRI assessment of the sacroiliac (SI) joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema.
Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant.
The total maximum (worst) score for all SI joints across 6 slices is 72. A negative change from Baseline indicates improvement.
Measured: Baseline and Week 14
Study 2: Percentage of Participants With BASDAI 50 Response at Week 14
The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale [NRS]) pertaining to symptoms experienced for the past week. For Questions 1 to 5 (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity.
A BASDAI 50 response is defined as improvement of 50% or more from Baseline in BASDAI score.
Measured: Baseline and Week 14
Study 2: Percentage of Participants With ASDAS Inactive Disease at Week 14
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:
- Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
- Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
- Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
- Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
- High-sensitivity C-reactive protein (hs-CRP) in mg/L.
The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score < 1.3.
Measured: Week 14
Study 2: Change From Baseline in Patient's Assessment of Total Back Pain at Week 14
Participants assessed their total back pain during the last week on a 0 to 10 numerical rating scale (NRS), where 0 represents no pain and 10 represents most severe pain.
Measured: Baseline and Week 14
Study 2: Change From Baseline in Patient's Assessment of Nocturnal Back Pain at Week 14
Participants assessed the amount of back pain at night over the last week on a 0 to 10 NRS, where 0 represents no pain and 10 represents most severe pain.
Measured: Baseline and Week 14
Study 2: Percentage of Participants With ASDAS Low Disease Activity at Week 14
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:
- Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
- Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
- Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
- Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
- High-sensitivity C-reactive protein (hs-CRP) in mg/L.
The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score < 2.1.
Measured: Week 14
Study 2: Percentage of Participants With ASAS Partial Remission at Week 14
ASAS partial remission (PR) is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains:
- Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity);
- Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
- Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
- Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Measured: Week 14
Study 2: Change From Baseline in BASFI at Week 14
The Bath Ankylosing Spondylitis Functional Index is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities such as putting on socks, bending, reaching, getting up from the floor or an armless chair, standing, climbing and other physical activities. Each item is scored on a NRS ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher scores indicating more functional limitations. A negative change from Baseline in BASFI indicates improvement.
Measured: Baseline and Week 14
Study 2: Change From Baseline in ASQoL at Week 14
The ASQoL consists of 18 items related to quality of life, including the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. Each item is answered as yes (scored as 1) or no (scored as 0).
Scores are summed to obtain the overall score which ranges from 0 to 18, where higher scores indicate a worse quality of life. A negative change from Baseline in ASQoL indicates improvement in quality of life.
Measured: Baseline and Week 14
Study 2: Change From Baseline in ASAS Health Index at Week 14
The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. Each of the 17 questions is answered by the participant as "I agree" (score = 1) or "I disagree" (score = 0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, where a higher score indicates a worse health status. A negative change from Baseline indicates improvement.
Measured: Baseline and Week 14
Study 2: Percentage of Participants Achieving an ASAS20 Response at Week 14
ASAS20 response was defined as an improvement of ≥ 20% and an absolute improvement of ≥ 1 unit (on a scale of 0 to 10) from Baseline in at least 3 of the following 4 domains, with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 units [on a scale of 0 to 10]) in the remaining domain:
- Patient's global assessment of disease activity, measured on a NRS from 0 (no activity) to 10 (severe activity);
- Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
- Function, measured by the BASFI which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
- Inflammation, measured by the mean of the 2 morning stiffness-related BASDAI NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Measured: Baseline and Week 14
Study 2: Change From Baseline in BASMI(Lin) at Week 14
The BASMI is a composite score based on 5 direct measurements of spinal mobility:
- cervical rotation (measured in degrees),
- tragus to wall distance (in centimeters [cm])
- lumbar side flexion (in cm),
- lumbar flexion (modified Schober's) (in cm) and
- intermalleolar distance (in cm).
Each measurement is converted to a linear score between 0 and 10. The total BASMI(lin) score is the average of the 5 scores and ranges from 0 to 10; the higher the BASMI(lin) score the more severe the patient's limitation of movement due to their ankylosing spondylitis. A negative change from Baseline indicates improvement.
Measured: Baseline and Week 14
Study 2: Change From Baseline in MASES at Week 14
The MASES evaluation was conducted to assess the presence or absence of enthesitis (inflammation of the entheses, or sites where tendons or ligaments insert into the bone) at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right. Each site was scored for presence (1) or absence (0) of enthesitis. The MASES is the sum of the 13 site scores, and ranges from 0 to 13, with higher scores indicating more inflammation of the entheses. A negative change from Baseline indicates improvement.
Measured: Baseline and Week 14
Study 2: Percentage of Participants Achieving an ASAS40 Response at Week 52
ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of > 0 units) in the potential remaining domain:
- Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity);
- Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
- Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
- Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Measured: Baseline and Week 52
Study 2: Change From Baseline in MRI SPARCC Score for the Spine at Week 14
In the SPARCC MRI assessment of the spine, the entire spine is evaluated for active inflammation (bone marrow edema). Six discovertebral units (DVU) representing the 6 most abnormal DVUs were selected to calculate the MRI Spine SPARCC score. For each of the 6 DVUs, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all three dimensions.
Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least one quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice.
The maximum (worst) overall score for all 6 DVUs is 108. A negative change from Baseline indicates improvement.
Measured: Baseline and Week 14
Study 2: Percentage of Participants Who Initiated Rescue Treatment Between Week 24 and Week 52
Participants who did not achieve an ASAS20 response at any 2 consecutive scheduled visits from Week 24 through Week 52 were to be rescued with standard of care treatment as described in the protocol.
Measured: Week 24, Week 32, Week 40, and Week 52
Study 2: Percentage of Participants With ASDAS Major Improvement at Week 52
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:
- Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
- Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
- Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
- Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
- High-sensitivity C-reactive protein (hs-CRP) in mg/L.
The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS < 1.3) and very high disease (ASDAS > 3.5). Major Improvement is defined as a change from Baseline of ≤ -2.0.
Measured: Baseline and Week 52
Study 2: Percentage of Participants With ASDAS Inactive Disease at Week 52
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:
- Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
- Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
- Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
- Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
- High-sensitivity C-reactive protein (hs-CRP) in mg/L.
The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score < 1.3.
Measured: Week 52
Study 2: Percentage of Participants With ASDAS Low Disease Activity at Week 52
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:
- Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
- Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
- Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
- Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
- High-sensitivity C-reactive protein (hs-CRP) in mg/L.
The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score < 2.1.
Measured: Week 52
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Nov 2019
- Study start26 Nov 2019
- Primary completion2 Sep 2021
- Study completion28 Feb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (13)Papers the sponsor has linked to this study.
- Other trials for SpondyloarthritisStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 734 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04169373
- Sponsor's protocol ID
- M19-944
- Other IDs
- 2022-501018-78-00
- Acronym
- SELECT-AXIS 2
- Status last verified
- Feb 2025
- First submitted
- 18 Nov 2019
- Last updated
- 24 Feb 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Publications
Baraliakos X, Bessette L, de Vlam K, Taylor PC, Biljan A, Urbanik J, Gao T, Jasion VS, Kato K, Lippe R, Magrey M. Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS Studies. Rheumatol Ther. 2026 Jun;13(3):611-628. doi: 10.1007/s40744-026-00834-5. Epub 2026 Mar 13.
PubMed 41824252Zhang X, Jia L, Lin X, Zhou L. Exhaustion-Resistant CD8 + T Cells in Ankylosing Spondylitis: A Proposed Three-Axis Model. Immunology. 2025 Dec;176(4):409-420. doi: 10.1111/imm.70044. Epub 2025 Oct 2.
PubMed 41039829Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y. Epub 2025 Aug 28.
PubMed 40875187Navarro-Compan V, Van den Bosch F, Sampaio-Barros PD, Ostor AJK, Parikh B, Kato K, Gao T, Stigler J, Ramiro S. Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease. RMD Open. 2025 Mar 4;11(1):e005110. doi: 10.1136/rmdopen-2024-005110.
PubMed 40037923Van den Bosch F, Deodhar A, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, Kishimoto M, Baraliakos X, Bu X, Lagunes-Galindo I, Song IH, Wung P, Kato K, Shmagel A. Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study. Arthritis Res Ther. 2025 Feb 4;27(1):23. doi: 10.1186/s13075-024-03441-3.
PubMed 39905436Poddubnyy D, Parikh B, Elewaut D, Navarro-Compan V, Siebert S, Paley M, Coombs D, Lagunes I, Biljan A, Nakasato P, Wung P, Lubrano E. Development of Extramusculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis. Arthritis Rheumatol. 2025 May;77(5):536-546. doi: 10.1002/art.43069. Epub 2025 Jan 24.
PubMed 39624020Baraliakos X, van der Heijde D, Sieper J, Inman RD, Kameda H, Maksymowych WP, Lagunes-Galindo I, Bu X, Wung P, Kato K, Shmagel A, Deodhar A. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study. Arthritis Res Ther. 2024 Nov 12;26(1):197. doi: 10.1186/s13075-024-03412-8.
PubMed 39533349Burmester GR, Stigler J, Rubbert-Roth A, Tanaka Y, Azevedo VF, Coombs D, Lagunes I, Lippe R, Wung P, Gensler LS. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatol Ther. 2024 Jun;11(3):737-753. doi: 10.1007/s40744-024-00671-4. Epub 2024 Apr 29.
PubMed 38683479Rubbert-Roth A, Kakehasi AM, Takeuchi T, Schmalzing M, Palac H, Coombs D, Liu J, Anyanwu SI, Lippe R, Curtis JR. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis. Rheumatol Ther. 2024 Feb;11(1):97-112. doi: 10.1007/s40744-023-00621-6. Epub 2023 Nov 20.
PubMed 37982966Kiltz U, Kishimoto M, Walsh JA, Sampaio-Barros P, Mittal M, Saffore CD, Wung P, Ganz F, Biljan A, Poddubnyy D. Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2. Rheumatol Ther. 2023 Aug;10(4):887-899. doi: 10.1007/s40744-023-00550-4. Epub 2023 May 16.
PubMed 37191738Navarro-Compan V, Baraliakos X, Magrey M, Ostor A, Saffore CD, Mittal M, Song IH, Ganz F, Stigler J, Deodhar A. Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis. Rheumatol Ther. 2023 Jun;10(3):679-691. doi: 10.1007/s40744-023-00536-2. Epub 2023 Feb 23.
PubMed 36820984Deodhar A, Van den Bosch F, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, Kishimoto M, Blanco R, Duan Y, Li Y, Pangan AL, Wung P, Song IH. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022 Jul 30;400(10349):369-379. doi: 10.1016/S0140-6736(22)01212-0.
PubMed 35908570van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, Zeng X, Sui Y, Bu X, Pangan AL, Wung P, Song IH. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022 Nov;81(11):1515-1523. doi: 10.1136/ard-2022-222608. Epub 2022 Jul 4.
PubMed 35788492